Source: yahoo_news
Source ID: yahoo:b1eb2e2619437402243506dff006e220:BEAM
URL: https://finance.yahoo.com/healthcare/articles/beam-therapeutics-present-initial-data-110000844.html?.tsrc=rss
Symbol: (BEAM)
Published: 2026-10-13 07:00:00 EDT
Time precision: minute
Title: Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology co